skip to Main Content

Drug Pricing

Keep up with our comprehensive coverage of administrative and legislative activity and what it means for industry, plans, providers, and patients.

Trump Administration Releases Drug Pricing Blueprint

The Department of Health and Human Services is seeking public input on a variety of proposals related to drug costs, providing stakeholders with an unprecedented opportunity to shape the administration's drug pricing policies.

Payer Trends in Oncology

The shift from volume to value has played a significant role in shaping current payer behavior in the oncology space.

Biosimilars Gain Widespread Adoption by Health Plans

New research from Avalere finds that most health plans are covering at least one of the two biosimilar products currently on the market.

Webinar: Drug Pricing: Where’s the Future Headed?

Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.

Back To Top